

Venous Thromboembolism Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/VC7B485B8BCCEN.html>

Date: May 2024

Pages: 134

Price: US\$ 6,499.00 (Single User License)

ID: VC7B485B8BCCEN

Abstracts

The 7 major venous thromboembolism markets reached a value of US\$ 3.8 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 7.0 Billion by 2034, exhibiting a growth rate (CAGR) of 5.71% during 2024-2034.

The venous thromboembolism market has been comprehensively analyzed in IMARC's new report titled "Venous Thromboembolism Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Venous thromboembolism refers to a life-threatening medical disorder characterized by the formation of blood clots within the veins, leading to the obstruction of blood flow. This disease mainly encompasses two primary conditions: deep vein thrombosis (DVT) and pulmonary embolism (PE). DVT occurs when a blood clot forms in one of the deep veins, typically in the arms or legs, whereas PE develops if a blood clot dislodges from its site of origin and travels to the lungs, blocking one of the pulmonary arteries. Individuals suffering from this ailment may experience swelling, redness and warmth in the affected limb, chest pain, shortness of breath, rapid heart rate, lightheadedness, loss of consciousness, blood in the cough, etc. The diagnosis of venous thromboembolism typically involves a combination of clinical evaluation, medical history assessment, and blood analysis. A D-dimer test is utilized to detect an elevated level of a protein fragment that may be indicative of the disease. Several other diagnostic procedures, such as MR venography, vascular ultrasound, pulse oximetry, etc., are also performed to confirm a diagnosis among patients.

The rising prevalence of chronic injuries to veins or surrounding tissues that can disrupt blood flow and trigger clot formation is primarily driving the venous thromboembolism market. In addition to this, the increasing incidences of several associated risk factors,

such as prolonged immobility, recent surgery or trauma, obesity, certain inherited blood clotting disorders, etc., are also bolstering the market growth. Moreover, the widespread adoption of direct oral anticoagulants, including apixaban, rivaroxaban, dabigatran, etc., which work by inhibiting the clotting factors in the blood, thereby preventing the formation of new clots, is further creating a positive outlook for the market. Besides this, the emerging popularity of inferior vena cava filters in patients who are unable to take pharmacological medicines is also propelling the market growth. This procedure involves the insertion of a tiny device into the large vein in the abdomen to prevent blood clots from reaching the lungs. Additionally, the escalating utilization of percutaneous mechanical thrombectomy for better and quicker removal of clots in the affected vein is expected to drive the venous thromboembolism market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the venous thromboembolism market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for venous thromboembolism and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the venous thromboembolism market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the venous thromboembolism market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the venous thromboembolism market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current venous thromboembolism marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the venous thromboembolism market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the venous thromboembolism market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the venous thromboembolism market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of venous thromboembolism across the seven major markets?

What is the number of prevalent cases (2018-2034) of venous thromboembolism by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of venous thromboembolism by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with venous thromboembolism across the seven major markets?

What is the size of the venous thromboembolism patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of venous thromboembolism?

What will be the growth rate of patients across the seven major markets?

Venous Thromboembolism: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for venous thromboembolism drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc.

related to the venous thromboembolism market?

What are the key regulatory events related to the venous thromboembolism market?

What is the structure of clinical trial landscape by status related to the venous thromboembolism market?

What is the structure of clinical trial landscape by phase related to the venous thromboembolism market?

What is the structure of clinical trial landscape by route of administration related to the venous thromboembolism market?

Contents

?1 Preface

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 VENOUS THROMBOEMBOLISM - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 VENOUS THROMBOEMBOLISM - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 VENOUS THROMBOEMBOLISM - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (2018-2034)
 - 7.2.4 Epidemiology by Gender (2018-2034)
 - 7.2.5 Diagnosed Cases (2018-2034)
 - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (2018-2034)
 - 7.3.4 Epidemiology by Gender (2018-2034)
 - 7.3.5 Diagnosed Cases (2018-2034)
 - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (2018-2034)
 - 7.4.4 Epidemiology by Gender (2018-2034)
 - 7.4.5 Diagnosed Cases (2018-2034)
 - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (2018-2034)
 - 7.5.4 Epidemiology by Gender (2018-2034)
 - 7.5.5 Diagnosed Cases (2018-2034)
 - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (2018-2034)
 - 7.6.4 Epidemiology by Gender (2018-2034)
 - 7.6.5 Diagnosed Cases (2018-2034)
 - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (2018-2034)
 - 7.8.4 Epidemiology by Gender (2018-2034)
 - 7.8.5 Diagnosed Cases (2018-2034)
 - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (2018-2034)
 - 7.9.4 Epidemiology by Gender (2018-2034)
 - 7.9.5 Diagnosed Cases (2018-2034)
 - 7.9.6 Patient Pool/Treated Cases (2018-2034)

8 VENOUS THROMBOEMBOLISM - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 VENOUS THROMBOEMBOLISM - UNMET NEEDS

10 VENOUS THROMBOEMBOLISM - KEY ENDPOINTS OF TREATMENT

11 VENOUS THROMBOEMBOLISM - MARKETED PRODUCTS

- 11.1 List of Venous Thromboembolism Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Pradaxa (Dabigatran etexilate) - Boehringer Ingelheim
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets
 - 11.1.2 Bevyxxa (Betrixaban) - Alexion AstraZeneca Rare Disease
 - 11.1.2.1 Drug Overview

- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets
- 11.1.3 Eliquis (Apixaban) - Bristol-Myers Squibb/Pfizer
 - 11.1.3.1 Drug Overview
 - 11.1.3.2 Mechanism of Action
 - 11.1.3.3 Regulatory Status
 - 11.1.3.4 Clinical Trial Results
 - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Savaysa (Edoxaban) - Daiichi Sankyo
 - 11.1.4.1 Drug Overview
 - 11.1.4.2 Mechanism of Action
 - 11.1.4.3 Regulatory Status
 - 11.1.4.4 Clinical Trial Results
 - 11.1.4.5 Sales Across Major Markets
- 11.1.5 Xarelto (Rivaroxaban) - Bayer/Johnson & Johnson Pharmaceutical Research & Development
 - 11.1.5.1 Drug Overview
 - 11.1.5.2 Mechanism of Action
 - 11.1.5.3 Regulatory Status
 - 11.1.5.4 Clinical Trial Results
 - 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 VENOUS THROMBOEMBOLISM - PIPELINE DRUGS

- 12.1 List of Venous Thromboembolism Pipeline Drugs Across the Top 7 Markets
 - 12.1.1 Abelacimab - Anthos Therapeutics
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action
 - 12.1.1.3 Clinical Trial Results
 - 12.1.1.4 Safety and Efficacy
 - 12.1.1.5 Regulatory Status
 - 12.1.2 Isoquercetin - Quercis Pharma
 - 12.1.2.1 Drug Overview
 - 12.1.2.2 Mechanism of Action
 - 12.1.2.3 Clinical Trial Results

- 12.1.2.4 Safety and Efficacy
- 12.1.2.5 Regulatory Status
- 12.1.3 TRX1 - TeaRx
 - 12.1.3.1 Drug Overview
 - 12.1.3.2 Mechanism of Action
 - 12.1.3.3 Clinical Trial Results
 - 12.1.3.4 Safety and Efficacy
 - 12.1.3.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. VENOUS THROMBOEMBOLISM - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. VENOUS THROMBOEMBOLISM – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 VENOUS THROMBOEMBOLISM - MARKET SCENARIO

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
 - 15.2.1 Venous Thromboembolism - Market Size
 - 15.2.1.1 Market Size (2018-2023)
 - 15.2.1.2 Market Forecast (2024-2034)
 - 15.2.2 Venous Thromboembolism - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
 - 15.3.1 Venous Thromboembolism - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
 - 15.3.2 Venous Thromboembolism - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
 - 15.3.3 Venous Thromboembolism - Access and Reimbursement Overview

15.4 Market Scenario - Germany

15.4.1 Venous Thromboembolism - Market Size

15.4.1.1 Market Size (2018-2023)

15.4.1.2 Market Forecast (2024-2034)

15.4.2 Venous Thromboembolism - Market Size by Therapies

15.4.2.1 Market Size by Therapies (2018-2023)

15.4.2.2 Market Forecast by Therapies (2024-2034)

15.4.3 Venous Thromboembolism - Access and Reimbursement Overview

15.5 Market Scenario - France

15.5.1 Venous Thromboembolism - Market Size

15.5.1.1 Market Size (2018-2023)

15.5.1.2 Market Forecast (2024-2034)

15.5.2 Venous Thromboembolism - Market Size by Therapies

15.5.2.1 Market Size by Therapies (2018-2023)

15.5.2.2 Market Forecast by Therapies (2024-2034)

15.5.3 Venous Thromboembolism - Access and Reimbursement Overview

15.6 Market Scenario - United Kingdom

15.6.1 Venous Thromboembolism - Market Size

15.6.1.1 Market Size (2018-2023)

15.6.1.2 Market Forecast (2024-2034)

15.6.2 Venous Thromboembolism - Market Size by Therapies

15.6.2.1 Market Size by Therapies (2018-2023)

15.6.2.2 Market Forecast by Therapies (2024-2034)

15.6.3 Venous Thromboembolism - Access and Reimbursement Overview

15.7 Market Scenario - Italy

15.7.1 Venous Thromboembolism - Market Size

15.7.1.1 Market Size (2018-2023)

15.7.1.2 Market Forecast (2024-2034)

15.7.2 Venous Thromboembolism - Market Size by Therapies

15.7.2.1 Market Size by Therapies (2018-2023)

15.7.2.2 Market Forecast by Therapies (2024-2034)

15.7.3 Venous Thromboembolism - Access and Reimbursement Overview

15.8 Market Scenario - Spain

15.8.1 Venous Thromboembolism - Market Size

15.8.1.1 Market Size (2018-2023)

15.8.1.2 Market Forecast (2024-2034)

15.8.2 Venous Thromboembolism - Market Size by Therapies

15.8.2.1 Market Size by Therapies (2018-2023)

15.8.2.2 Market Forecast by Therapies (2024-2034)

- 15.8.3 Venous Thromboembolism - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Venous Thromboembolism - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Venous Thromboembolism - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Venous Thromboembolism - Access and Reimbursement Overview

16 VENOUS THROMBOEMBOLISM - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 VENOUS THROMBOEMBOLISM MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 VENOUS THROMBOEMBOLISM MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Venous Thromboembolism Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/VC7B485B8BCCEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/VC7B485B8BCCEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

